CVKD: תחזית צמיחת רווחים לשנה הבאה Cadrenal Therapeutics, Inc

Cadrenal Therapeutics - לוגו גרפי של המנפיק CVKD

The earnings per share growth model for next year is based on the digitalization of data collection during clinical trials, which reduces costs. The stability of research in the US is ensured by a neutral geopolitical climate. Meanwhile, 22.10 represents the current metric, highlighting the potential of Tecarfarin in treating thrombosis in dialysis patients to capture the anticoagulant market for Cadrenal Therapeutics (CVKD).

CVKD - צמיחה צפויה ברווח נקי למניה בשנה הבאה Cadrenal Therapeutics Inc. בטווח 28.04.2023 - 17.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת Cadrenal Therapeutics, Inc. (CVKD)

ניתוח כללי של החברה:CVKD, Cadrenal Therapeutics
מוצרים מוגמרים של cadrenal.com

To verify the credit quality of Cadrenal Therapeutics (CVKD), the analyst evaluates the company's ability to generate future cash flow. Business sustainability is based on the commercialization of Tecarfarin for dialysis patients, which directly impacts net income expectations. By analyzing the historical trend of the next year's EPS forecast, the investor can see the consolidated expert opinion on profit growth rates, allowing for the timely identification of risks regarding asset undervaluation or overheating.